 Edith Zemanick
Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 66 | 2023 | 964 | 13.310 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 18 | 2023 | 288 | 4.120 |
Why?
| | Pseudomonas Infections | 12 | 2023 | 193 | 3.280 |
Why?
| | Anti-Bacterial Agents | 23 | 2023 | 1510 | 3.040 |
Why?
| | Pseudomonas aeruginosa | 13 | 2023 | 305 | 2.960 |
Why?
| | Microbiota | 12 | 2023 | 656 | 2.940 |
Why?
| | Chloride Channel Agonists | 6 | 2023 | 58 | 2.470 |
Why?
| | Sputum | 9 | 2021 | 290 | 2.250 |
Why?
| | Quinolones | 7 | 2021 | 98 | 1.630 |
Why?
| | Respiratory System | 6 | 2021 | 141 | 1.600 |
Why?
| | Oropharynx | 3 | 2021 | 41 | 1.420 |
Why?
| | Metagenome | 4 | 2013 | 121 | 1.310 |
Why?
| | Specimen Handling | 3 | 2021 | 165 | 1.310 |
Why?
| | DNA, Bacterial | 6 | 2019 | 314 | 1.300 |
Why?
| | Lung | 9 | 2023 | 3664 | 1.180 |
Why?
| | Aminophenols | 10 | 2023 | 112 | 1.110 |
Why?
| | Inflammation | 6 | 2017 | 2566 | 1.050 |
Why?
| | Respiratory Tract Infections | 4 | 2018 | 331 | 1.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2019 | 613 | 1.000 |
Why?
| | Anti-Infective Agents | 2 | 2023 | 227 | 0.920 |
Why?
| | Sweat | 4 | 2022 | 38 | 0.910 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.830 |
Why?
| | Indoles | 2 | 2021 | 316 | 0.820 |
Why?
| | Benzodioxoles | 7 | 2023 | 84 | 0.800 |
Why?
| | Chlorides | 2 | 2022 | 137 | 0.790 |
Why?
| | RNA, Ribosomal, 16S | 5 | 2023 | 514 | 0.760 |
Why?
| | Microbial Sensitivity Tests | 3 | 2021 | 302 | 0.750 |
Why?
| | Child | 34 | 2023 | 19129 | 0.740 |
Why?
| | Humans | 67 | 2023 | 118972 | 0.720 |
Why?
| | Drug Resistance, Bacterial | 2 | 2021 | 155 | 0.710 |
Why?
| | Pyrazoles | 1 | 2021 | 363 | 0.640 |
Why?
| | Genetic Therapy | 4 | 2023 | 267 | 0.610 |
Why?
| | Bacteria | 8 | 2023 | 757 | 0.600 |
Why?
| | beta-Lactams | 3 | 2023 | 28 | 0.590 |
Why?
| | Nasopharynx | 1 | 2016 | 64 | 0.550 |
Why?
| | Carrier State | 1 | 2016 | 57 | 0.530 |
Why?
| | Lung Diseases | 3 | 2018 | 718 | 0.500 |
Why?
| | Adolescent | 21 | 2023 | 18480 | 0.500 |
Why?
| | Bacteria, Anaerobic | 2 | 2011 | 19 | 0.500 |
Why?
| | Drug Combinations | 5 | 2022 | 291 | 0.490 |
Why?
| | Aminopyridines | 3 | 2021 | 85 | 0.490 |
Why?
| | Vital Capacity | 1 | 2014 | 260 | 0.480 |
Why?
| | Mutation | 12 | 2023 | 3457 | 0.480 |
Why?
| | Male | 33 | 2021 | 57801 | 0.470 |
Why?
| | Saliva | 1 | 2015 | 188 | 0.470 |
Why?
| | Female | 34 | 2022 | 61564 | 0.460 |
Why?
| | Respiratory Sounds | 1 | 2014 | 119 | 0.460 |
Why?
| | Precision Medicine | 1 | 2016 | 363 | 0.430 |
Why?
| | Bronchiectasis | 1 | 2013 | 105 | 0.420 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1012 | 0.390 |
Why?
| | Age Factors | 1 | 2017 | 2995 | 0.370 |
Why?
| | Disease Management | 1 | 2014 | 571 | 0.360 |
Why?
| | Cytokines | 2 | 2015 | 1900 | 0.350 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 1798 | 0.350 |
Why?
| | Disease Progression | 5 | 2022 | 2490 | 0.340 |
Why?
| | Pneumonia, Bacterial | 1 | 2009 | 110 | 0.330 |
Why?
| | Infant | 7 | 2023 | 8293 | 0.330 |
Why?
| | Respiratory Function Tests | 4 | 2021 | 526 | 0.320 |
Why?
| | Biofilms | 2 | 2020 | 231 | 0.310 |
Why?
| | Young Adult | 10 | 2021 | 10793 | 0.300 |
Why?
| | Child, Preschool | 10 | 2023 | 9491 | 0.290 |
Why?
| | Prospective Studies | 7 | 2023 | 6471 | 0.260 |
Why?
| | Oxygen | 2 | 2020 | 854 | 0.260 |
Why?
| | Genotype | 2 | 2021 | 1882 | 0.230 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2016 | 190 | 0.220 |
Why?
| | Central Venous Catheters | 1 | 2023 | 42 | 0.220 |
Why?
| | Catheter-Related Infections | 1 | 2023 | 60 | 0.220 |
Why?
| | Quality Improvement | 3 | 2019 | 963 | 0.210 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 21 | 0.210 |
Why?
| | Catheterization, Peripheral | 1 | 2023 | 107 | 0.210 |
Why?
| | Catheterization, Central Venous | 1 | 2023 | 95 | 0.210 |
Why?
| | Staphylococcal Infections | 2 | 2016 | 346 | 0.200 |
Why?
| | Antimicrobial Cationic Peptides | 2 | 2019 | 78 | 0.200 |
Why?
| | Trachea | 1 | 2023 | 226 | 0.200 |
Why?
| | Venous Thrombosis | 1 | 2023 | 147 | 0.200 |
Why?
| | Tobramycin | 3 | 2023 | 50 | 0.200 |
Why?
| | Adult | 10 | 2023 | 31512 | 0.190 |
Why?
| | Pseudomonas | 2 | 2022 | 27 | 0.180 |
Why?
| | Respiratory System Agents | 1 | 2020 | 22 | 0.180 |
Why?
| | Bacteriological Techniques | 1 | 2019 | 66 | 0.170 |
Why?
| | Luminescent Measurements | 1 | 2019 | 72 | 0.170 |
Why?
| | Delphi Technique | 1 | 2019 | 164 | 0.170 |
Why?
| | International Cooperation | 1 | 2019 | 177 | 0.170 |
Why?
| | Critical Pathways | 1 | 2019 | 79 | 0.170 |
Why?
| | Genetic Variation | 2 | 2021 | 926 | 0.170 |
Why?
| | Bacterial Infections | 1 | 2020 | 227 | 0.160 |
Why?
| | Drug Prescriptions | 1 | 2020 | 248 | 0.160 |
Why?
| | Alleles | 1 | 2021 | 832 | 0.160 |
Why?
| | Immunoglobulin A | 1 | 2019 | 174 | 0.160 |
Why?
| | Treatment Outcome | 7 | 2020 | 9342 | 0.160 |
Why?
| | Aptamers, Nucleotide | 1 | 2019 | 74 | 0.160 |
Why?
| | Safety | 1 | 2019 | 304 | 0.160 |
Why?
| | Case-Control Studies | 4 | 2019 | 3171 | 0.160 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2018 | 135 | 0.150 |
Why?
| | Pilot Projects | 2 | 2023 | 1419 | 0.150 |
Why?
| | Volatile Organic Compounds | 1 | 2018 | 59 | 0.150 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2019 | 206 | 0.150 |
Why?
| | Consensus | 1 | 2019 | 534 | 0.150 |
Why?
| | Membrane Transport Modulators | 1 | 2017 | 7 | 0.150 |
Why?
| | Blood Proteins | 1 | 2019 | 248 | 0.150 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 32 | 0.150 |
Why?
| | Respiratory Mucosa | 1 | 2019 | 254 | 0.150 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2016 | 37 | 0.150 |
Why?
| | Azithromycin | 2 | 2023 | 81 | 0.140 |
Why?
| | Rifampin | 1 | 2017 | 69 | 0.140 |
Why?
| | United States | 4 | 2018 | 12555 | 0.140 |
Why?
| | Foundations | 1 | 2016 | 22 | 0.140 |
Why?
| | Cohort Studies | 2 | 2017 | 5116 | 0.140 |
Why?
| | Longitudinal Studies | 3 | 2021 | 2513 | 0.140 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 394 | 0.140 |
Why?
| | Patient Selection | 1 | 2019 | 676 | 0.130 |
Why?
| | Infant, Newborn | 3 | 2023 | 5255 | 0.130 |
Why?
| | Cholesterol Esters | 1 | 2015 | 9 | 0.130 |
Why?
| | Bronchi | 1 | 2016 | 242 | 0.130 |
Why?
| | Double-Blind Method | 1 | 2019 | 1687 | 0.130 |
Why?
| | Pulmonary Medicine | 1 | 2016 | 85 | 0.130 |
Why?
| | Immunoglobulin G | 1 | 2019 | 788 | 0.130 |
Why?
| | Enterobacteriaceae | 1 | 2015 | 33 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 969 | 0.130 |
Why?
| | Regression Analysis | 1 | 2017 | 983 | 0.130 |
Why?
| | Radiography | 1 | 2017 | 861 | 0.130 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2019 | 334 | 0.130 |
Why?
| | Staphylococcus | 1 | 2015 | 68 | 0.130 |
Why?
| | Enterobacteriaceae Infections | 1 | 2015 | 34 | 0.130 |
Why?
| | Administration, Oral | 3 | 2023 | 756 | 0.120 |
Why?
| | Achromobacter denitrificans | 1 | 2014 | 1 | 0.120 |
Why?
| | Stenotrophomonas maltophilia | 1 | 2014 | 2 | 0.120 |
Why?
| | Retrospective Studies | 4 | 2023 | 12978 | 0.120 |
Why?
| | Spirometry | 1 | 2015 | 263 | 0.120 |
Why?
| | Genotyping Techniques | 1 | 2014 | 75 | 0.120 |
Why?
| | Biomarkers | 5 | 2020 | 3588 | 0.120 |
Why?
| | Forced Expiratory Volume | 3 | 2020 | 520 | 0.120 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1474 | 0.120 |
Why?
| | Chronic Disease | 1 | 2019 | 1636 | 0.120 |
Why?
| | Genetic Markers | 1 | 2014 | 348 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 381 | 0.110 |
Why?
| | Proteomics | 1 | 2019 | 876 | 0.110 |
Why?
| | Feces | 1 | 2015 | 396 | 0.110 |
Why?
| | Leukocyte Elastase | 1 | 2012 | 80 | 0.110 |
Why?
| | Animals | 4 | 2019 | 33381 | 0.110 |
Why?
| | Proteolysis | 1 | 2012 | 146 | 0.100 |
Why?
| | Administration, Inhalation | 2 | 2023 | 656 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 755 | 0.100 |
Why?
| | Quality of Life | 2 | 2023 | 2366 | 0.100 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2011 | 17 | 0.100 |
Why?
| | Biota | 1 | 2011 | 37 | 0.100 |
Why?
| | Phenotype | 1 | 2019 | 3003 | 0.100 |
Why?
| | Neonatal Screening | 1 | 2012 | 152 | 0.100 |
Why?
| | Middle Aged | 3 | 2021 | 27617 | 0.090 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 531 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 3057 | 0.090 |
Why?
| | Blood Glucose | 1 | 2018 | 1939 | 0.090 |
Why?
| | Morbidity | 1 | 2009 | 296 | 0.080 |
Why?
| | Pediatrics | 1 | 2016 | 985 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1440 | 0.080 |
Why?
| | Gastrointestinal Microbiome | 1 | 2015 | 548 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4552 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2014 | 4596 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 1945 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2010 | 2874 | 0.060 |
Why?
| | Catheters, Indwelling | 1 | 2023 | 81 | 0.050 |
Why?
| | Aged | 1 | 2021 | 19657 | 0.050 |
Why?
| | Anaerobiosis | 1 | 2021 | 50 | 0.050 |
Why?
| | Styrenes | 1 | 2020 | 5 | 0.050 |
Why?
| | Colistin | 1 | 2020 | 10 | 0.050 |
Why?
| | Pyridinium Compounds | 1 | 2020 | 14 | 0.050 |
Why?
| | Porphyrins | 1 | 2020 | 17 | 0.050 |
Why?
| | Dysbiosis | 1 | 2021 | 147 | 0.040 |
Why?
| | Serologic Tests | 1 | 2019 | 52 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 88 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 120 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2019 | 117 | 0.040 |
Why?
| | Homozygote | 1 | 2018 | 190 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2019 | 123 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 296 | 0.040 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 368 | 0.040 |
Why?
| | Biological Availability | 1 | 2017 | 126 | 0.040 |
Why?
| | Minocycline | 1 | 2016 | 28 | 0.040 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 52 | 0.040 |
Why?
| | Chlorhexidine | 1 | 2016 | 22 | 0.040 |
Why?
| | Anti-Infective Agents, Local | 1 | 2016 | 42 | 0.040 |
Why?
| | ROC Curve | 1 | 2018 | 473 | 0.040 |
Why?
| | Nanoparticles | 1 | 2020 | 325 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2017 | 151 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2017 | 187 | 0.030 |
Why?
| | Drug Interactions | 1 | 2017 | 352 | 0.030 |
Why?
| | Capsule Endoscopes | 1 | 2015 | 8 | 0.030 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2015 | 32 | 0.030 |
Why?
| | Permeability | 1 | 2015 | 156 | 0.030 |
Why?
| | Autoimmunity | 1 | 2019 | 831 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 245 | 0.030 |
Why?
| | Decision Making | 1 | 2019 | 809 | 0.030 |
Why?
| | Genetic Carrier Screening | 1 | 2012 | 23 | 0.030 |
Why?
| | Trypsinogen | 1 | 2012 | 9 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 1194 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2012 | 115 | 0.030 |
Why?
| | DNA | 1 | 2018 | 1388 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3443 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2016 | 759 | 0.020 |
Why?
| | Proteins | 1 | 2015 | 938 | 0.020 |
Why?
| | Genes, rRNA | 1 | 2007 | 39 | 0.020 |
Why?
| | Genes, Bacterial | 1 | 2007 | 162 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 9000 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2871 | 0.010 |
Why?
|
|
Zemanick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|